Brief: Cullinan Therapeutics Receives U.S. FDA Clearance Of Investigational New Drug Application For CLN-978 Administered Subcutaneously In Patients With Moderate To Severe Systemic Lupus Erythematosus
16/10/2024 12:37
Oct 16 (Reuters) - Cullinan Therapeutics Inc CGEM.O :
* CULLINAN THERAPEUTICS RECEIVES U.S. FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR CLN-978 ADMINISTERED
SUBCUTANEOUSLY IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC
LUPUS ERYTHEMATOSUS
Source text for Eikon: ID:nGNXbX2QSn
Further company coverage: CGEM.O
((Reuters.Briefs@thomsonreuters.com;))